Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
73
APLS Quote, Financials, Valuation and Earnings
Last price:
$40.41
Seasonality move
:
9.65%
Day range:
$40.35 - $40.48
52-week range:
$16.10 - $40.48
Dividend yield:
0%
P/E ratio:
327.37x
P/S ratio:
5.12x
P/B ratio:
13.96x
Volume:
10.3M
Avg. volume:
6.5M
1-year change:
75.7%
Market cap:
$5.2B
Revenue:
$1B
EPS (TTM):
$0.12
Analysts' Opinion
-
Consensus RatingApellis Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 17 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $38.60, Apellis Pharmaceuticals, Inc. has an estimated downside of -4.48% from its current price of $40.41.
-
Price Target UpsideAccording to analysts, the highest upside price target is $41.00 representing -- upside increase from its current price of $40.41.
Fair Value
-
According to the consensus of 20 analysts, Apellis Pharmaceuticals, Inc. has -4.48% downside to fair value with a price target of $38.60 per share.
APLS vs. S&P 500
-
Over the past 5 trading days, Apellis Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Apellis Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apellis Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Apellis Pharmaceuticals, Inc. reported revenues of $199.9M.
Earnings Growth
-
Apellis Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Apellis Pharmaceuticals, Inc. reported earnings per share of -$0.47.
Enterprise value:
5.2B
EV / Invested capital:
--
Price / LTM sales:
5.12x
EV / EBIT:
93.32x
EV / Revenue:
5.15x
PEG ratio (5yr expected):
--
EV / Free cash flow:
114.90x
Price / Operating cash flow:
114.11x
Enterprise value / EBITDA:
90.76x
Gross Profit (TTM):
$900.3M
Return On Assets:
2.41%
Net Income Margin (TTM):
2.23%
Return On Equity:
8.48%
Return On Invested Capital:
3.04%
Operating Margin:
-25.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $396.6M | $781.4M | $1B | $212.5M | $199.9M | |
| Gross Profit | $338.1M | $662.3M | $900.3M | $171.7M | $170.2M | |
| Operating Income | -$517.1M | -$165M | $55.4M | -$26.2M | -$51.1M | |
| EBITDA | -$515.4M | -$163.2M | $57M | -$25.7M | -$50.8M | |
| Diluted EPS | -$4.48 | -$1.60 | $0.12 | -$0.29 | -$0.47 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $824M | $719.5M | $766.3M | $789M | $1B | |
| Total Assets | $881.8M | $760.2M | $788.7M | $885.1M | $1.1B | |
| Current Liabilities | $131.8M | $167.6M | $247.6M | $185.5M | $323.6M | |
| Total Liabilities | $683.1M | $590.3M | $594.2M | $656.5M | $705.1M | |
| Total Equity | $198.7M | $169.9M | $194.5M | $228.5M | $370.1M | |
| Total Debt | $206.1M | $107.1M | $104.5M | $463M | $467.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$594.7M | -$87.9M | $45.3M | $19.4M | -$14.2M | |
| Cash From Investing | -$674K | -$403K | -$313K | -$20K | -$108K | |
| Cash From Financing | $394.5M | $149.2M | $8.9M | -$4M | $1.3M | |
| Free Cash Flow | -$595.5M | -$88.3M | $45M | $19.3M | -$14.3M | |
APLS
Sector
Market Cap
$5.2B
$23.9M
Price % of 52-Week High
--
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.3%
-1.9%
1-Year Price Total Return
75.7%
-18.29%
Beta (5-Year)
-0.189
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$25.96
200-day SMA
Buy
Level
$22.75
Bollinger Bands (100)
Buy
Level
18.27 - 26.27
Chaikin Money Flow
Sell
Level
-124.7M
20-day SMA
Buy
Level
$21.62
Relative Strength Index (RSI14)
Buy
Level
87.46
ADX Line
Buy
Level
46.99
Williams %R
Sell
Level
-0.296
50-day SMA
Buy
Level
$21.88
MACD (12, 26)
Buy
Level
3.34
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
26.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.6587)
Sell
CA Score
(Annual)
Level (-0.7014)
Buy
Beneish M-Score
(Annual)
Level (-2.4296)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-4.579)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, APLS has received 3 Buy ratings 17 Hold ratings, and 0 Sell ratings. The APLS average analyst price target in the past 3 months is $38.60.
-
Where Will Apellis Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apellis Pharmaceuticals, Inc. share price will drop to $38.60 per share over the next 12 months.
-
What Do Analysts Say About Apellis Pharmaceuticals, Inc.?
Analysts are divided on their view about Apellis Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apellis Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $21.00.
-
What Is Apellis Pharmaceuticals, Inc.'s Price Target?
The price target for Apellis Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $38.60 according to 20 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is APLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apellis Pharmaceuticals, Inc. is a Hold. 17 of 20 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of APLS?
You can purchase shares of Apellis Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apellis Pharmaceuticals, Inc. shares.
-
What Is The Apellis Pharmaceuticals, Inc. Share Price Today?
Apellis Pharmaceuticals, Inc. was last trading at $40.41 per share. This represents the most recent stock quote for Apellis Pharmaceuticals, Inc.. Yesterday, Apellis Pharmaceuticals, Inc. closed at $40.41 per share.
-
How To Buy Apellis Pharmaceuticals, Inc. Stock Online?
In order to purchase Apellis Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get APLS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
APLS
Sector
P/E ratio
327.37x
21.37x
PEG ratio
--
-0.01x
P/B ratio
13.96x
1.72x
Price / LTM sales
5.12x
1.44x
Growth Metrics
APLS
Sector
Revenue growth
-5.94%
3.44%
Earnings growth
-59.44%
14.97%
Revenue (5-year growth)
31.98%
6.27%
Earnings forecast
-$0.33
-$0.22
Profitability
APLS
Sector
Profitability FY 2025
$901.5M
$2.4M
Return on invested capital
3.04%
-33.43%
Return on assets
2.41%
-29.45%
Return on equity
8.48%
-40.29%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
7
Estimated Next Earnings Date
May
26
Balance Sheet
APLS
Sector
Total cash
$467.8M
$25.6M
Short term investments
--
$22.7M
Total assets
$1.1B
$70.4M
Long term debt
$467.3M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
